论文部分内容阅读
目的探究非小细胞肺癌化疗后采用脱氧核苷酸治疗对骨髓抑制的临床应用价值。方法 47例非小细胞肺癌患者随机分为治疗组26例,对照组21例。均给予化疗,化疗周期内治疗组同时给予脱氧核苷酸注射液联合粒细胞集落刺激因子治疗;对照组仅给予粒细胞集落刺激因子皮下注射。评价化疗后7、21 d的白细胞、血小板、免疫功能、体重、生活质量评分及粒细胞集落刺激因子的不良反应。结果治疗组7 d后WBC计数为(5.6±1.5)×109/L,血小板计数为(84.2±16.2)×109/L,WBC恢复正常人数占92.3%,Ⅲ度+Ⅳ度骨髓抑制发生率为11.5%。对照组分别为(3.2±1.6)×109/L,(68.9±20.2)×109/L,66.7%,57.1%。两组比较差异具有统计学意义(P<0.05)。另外两组治疗14 d后,治疗组CD3+[(68.3±8.1)%VS(54.3±6.5)%],CD4+[(36.2±14.5)%VS(30.5±15.0)%],NK细胞[(34.5±12.8)%VS(27.5±8.9)%],体重增加量[(1.6±0.5)kg VS(-0.5±0.2)kg]水平均高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗过程中,治疗组肌肉疼痛/乏力、肝损伤不良事件发生率均为3.8%,对照组分别为33.3%、38.0%。结论脱氧核苷酸注射液可提高白细胞、血小板水平,提高免疫功能及体重,减少粒细胞集落刺激因子的不良反应。
Objective To investigate the clinical value of deoxynucleotide treatment for bone marrow suppression in patients with non-small cell lung cancer after chemotherapy. Methods Forty-seven patients with non-small cell lung cancer were randomly divided into treatment group (n = 26) and control group (n = 21). All patients in the chemotherapy group were treated with dexonucleoside injection and granulocyte colony-stimulating factor simultaneously. The control group was given only subcutaneous injection of granulocyte colony-stimulating factor. Evaluation of leukocytes, platelets, immune function, body weight, quality of life scores and adverse effects of granulocyte colony stimulating factor at 7 and 21 days after chemotherapy were evaluated. Results The WBC count was (5.6 ± 1.5) × 109 / L and the platelet count was (84.2 ± 16.2) × 109 / L in 7 days after treatment in the treatment group, 92.3% in the normal WBC group, and the third and fourth degree myelosuppression was 11.5%. The control group were (3.2 ± 1.6) × 109 / L, (68.9 ± 20.2) × 109 / L, 66.7%, 57.1% respectively. The difference between the two groups was statistically significant (P <0.05). In the other two groups, the levels of CD3 + [(68.3 ± 8.1)% VS (54.3 ± 6.5)%] and CD4 + [(36.2 ± 14.5)% VS (30.5 ± 15.0)%] 12.8% VS 27.5 ± 8.9%] and body weight gain [(1.6 ± 0.5) kg VS (-0.5 ± 0.2) kg], respectively, with significant difference between the two groups (P <0.05 ). During the treatment, the incidence of muscle pain / fatigue and liver injury in the treatment group were 3.8% and 33.3% and 38.0% respectively in the control group. Conclusion Deoxynucleotide injection can improve leukocyte and platelet levels, improve immune function and body weight, and reduce the adverse reactions of granulocyte-colony stimulating factor.